Patent Acquisition Opportunity: Temporary Aortic Valve & Structural Heart Technologies

Hilco Global presents an opportunity to acquire a focused portfolio of patented technologies relating to temporary aortic valve support, transcatheter aortic valve replacement (TAVR) procedures, and synchronized aortic counterpulsation. Developed by an experienced interventional cardiologist and biomedical engineer, the portfolio addresses a key structural-heart challenge: maintaining hemodynamic stability and limiting aortic regurgitation while the native valve is treated and a permanent prosthetic valve is positioned or deployed.

Temporary Aortic Valve Support — Catheter-based devices designed to inhibit regurgitant flow during periods of compromised native aortic-valve function.

Flexible Occluding Membrane Technology — Valve structures incorporating flexible membranes that transition between expanded and collapsed
configurations in response to the cardiac cycle.

TAVR Procedural Support — Systems and methods intended to support circulation during preparation, positioning, and deployment of percutaneous replacement valves.

Synchronized Balloon Counterpulsation — Expandable structures synchronized with systole and diastole to influence aortic flow and provide temporary hemodynamic assistance.

Collectively, the portfolio provides coverage extending beyond a single device embodiment to include devices, methods of use, procedural applications, catheter systems, and cardiovascular flow-management techniques.

• Highly focused structural-heart portfolio. Coherent patent estate centered on a single cardiovascular technology platform.
• Longstanding priority positions. Certain families trace to the early development period of catheter-based aortic valve replacement.
• Multiple generations of innovation. Coverage progresses from early temporary-valve and balloon concepts to later flexible-membrane architectures.
• Continuing patent prosecution. A U.S. continuation application remains in prosecution, potentially offering an acquirer additional claim-development flexibility, subject to prosecution history and applicable law.
• Potential defensive and offensive value. Potential applications include portfolio strengthening, product differentiation, cross-licensing leverage, competitive positioning, and licensing or enforcement strategies.

The available portfolio includes 17 active patent records across multiple families. Core technology areas include:

Hilco Global is seeking non-binding indications of interest to acquire the assets of Hocor Cardiovascular Technologies. Interested parties should reach out to Hilco Global to obtain additional information about the opportunity.